No Data
No Data
AnGes --- HGF gene therapy product "Colatagen" presented at the American College of Cardiology academic session.
Anges <4563> announced on the 19th that it reported the clinical trial results of the HGF gene therapy product "Colategen" at the American Heart Association's scientific session, scheduled for November 18, 2024. The report on the results of the late-stage Phase II clinical trial of Colategen (LEGEND1 trial) was selected for the Featured Science Session at the American Heart Association conference held in Chicago, Illinois, USA, from November 16-18, 2024.
Volume change rate ranking (1 PM) - Agile, Itoki, etc. are ranked.
In the volume change rate ranking, comparing the recent 5-day average volume with the volume on the distribution day allows understanding of the trends in market participation interests, etc. ■ Top Volume Change Rate [As of November 19, 13:32] (Comparison of recent 5-day average volume) Code ⇒ Stock ⇒ Volume ⇒ 5-day average volume ⇒ Volume change ratio ⇒ Price change ratio ＜3978＞ Macromill 3612400109051.12349.33% 0.0579% ＜6573＞ Agile 1303350.
Insider decrases its stake in AnGes(4563.JP) to 27.38%
On Nov 12, CANTOR FITZGERALD EUROPE submitted the Change Report to Ministry of Finance. The report shows that CANTOR FITZGERALD EUROPE decreased their holdings in $AnGes(4563.JP)$, with their joint
Anges---In the third quarter, there was a significant increase in revenue, with the number of contracted newborn screening steadily increasing.
On the 8th, Anges <4563> announced its consolidated financial results for the third quarter of the fiscal year ending December 2024 (January-September 24). The revenue increased by 359.4% compared to the same period last year to 0.471 billion yen, operating loss was 7.042 billion yen (compared to a loss of 9.207 billion yen in the same period last year), ordinary loss was 7.05 billion yen (compared to a loss of 4.72 billion yen), and quarterly net loss attributable to the parent company's shareholders was 7.156 billion yen (compared to a loss of 4.798 billion yen). The business income for the cumulative period of this third quarter showed a significant increase compared to the same period last year.
AnGes 9-Mos Loss Y7.16B Vs Loss Y4.80B
AnGes Sees FY Loss Y8.65B
No Data
No Data